Translational Neural Devices (R61/R33 - Clinical Trial Optional)
ID: 352612Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352612

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-151.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at supporting the development of therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. This grant program encourages investigators to conduct small clinical studies and translational activities, including non-clinical safety and efficacy testing, and obtaining necessary regulatory approvals, with a focus on advancing innovative device designs that cannot be fully assessed through non-clinical methods. The program emphasizes health equity and diverse representation in research, with applications opening on April 29, 2024, and closing on January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-151-Full-Announcement.html
    Please provide the text you would like me to summarize.
    PAR-24-151.html
    The Department of Health and Human Services, through the National Institutes of Health, has issued a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of low-risk therapeutic and diagnostic devices for neurological disorders. This funding mechanism includes two phases: R61 for non-clinical testing leading to IRB approval and R33 for small clinical studies, requiring adherence to strict guidelines, including a Plan for Enhancing Diverse Perspectives (PEDP). Key dates for application are set between May 2024 and January 2027, with applications reviewed for scientific merit and compliance with NIH policies.
    Similar Opportunities
    BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative to support the development of next-generation devices for recording and modulation in the human central nervous system. This initiative aims to facilitate translational activities and small clinical studies focused on therapeutic and diagnostic devices for CNS disorders, particularly those requiring Investigational Device Exemptions (IDE) for significant risk studies. The program emphasizes milestone-driven cooperative agreements, collaboration among diverse research teams, and the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to promote equitable access in research. With an annual budget of $10 million available for approximately 5 to 7 awards, interested applicants can find more information and apply starting April 29, 2024, by contacting NIH Grants Information at grantsinfo@nih.gov.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative to support clinical studies aimed at advancing next-generation devices for recording and modulation within the human central nervous system (CNS). This initiative encourages proposals for early-stage clinical investigations, including first-in-human studies, that focus on treating CNS disorders and enhancing understanding of brain functions, particularly through Significant Risk studies requiring FDA Investigational Device Exemptions (IDEs) for chronic implants. The NIH plans to allocate approximately $10 million annually to fund 5 to 7 projects, emphasizing the importance of collaborations with device manufacturers through a public-private partnership program, and requires a Plan for Enhancing Diverse Perspectives as part of the application. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 28, 2027.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This grant supports projects that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices, focusing on improving spatial and temporal precision and enabling multi-focal approaches for effective treatment delivery. The initiative is crucial for addressing clinical limitations in mental health technologies and encourages collaboration among multidisciplinary teams with expertise in neuroscience, engineering, and regulatory affairs. Interested applicants can apply for up to $275,000 over a two-year project period, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-038.html.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at fostering the development of innovative brain stimulation devices or enhancing existing FDA-approved devices for treating mental health disorders. The initiative seeks applications from multi-disciplinary teams with expertise in neuroscience, engineering, clinical practices, and regulatory matters, focusing on creating devices that offer improved spatial and temporal resolution compared to current technologies. This funding opportunity is critical for advancing treatment methods in mental health care, with no budget limits as long as costs align with project needs, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation" (R21 Clinical Trial Optional). This initiative aims to support research that addresses ethical questions throughout the design, testing, and implementation phases of bionic and robotic devices, focusing on issues such as autonomy, informed consent, and equitable access to technology. A total of $2 million is available to fund 4-5 awards, with each project budget capped at $275,000 over two years. Interested applicants must submit their proposals by January 26, 2024, and can find additional details and guidelines at the NIH grants website or by contacting grantsinfo@nih.gov.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) funding opportunity, aimed at supporting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies of therapeutic agents for neurological and neuromuscular disorders. This grant follows the R61/R33 phased award mechanism, where the R61 phase focuses on preparation and characterization, while the R33 phase emphasizes efficacy studies, with a critical transition contingent upon meeting specific milestones. The program encourages collaboration among various organizations, including nonprofit entities and academic institutions, to accelerate the development of promising therapies, with awards capped at $750,000 over a maximum project duration of three years. Interested applicants can find more information and application instructions at the NIH grants website, and the deadline for submissions is October 20, 2027.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative for the development of clinical-grade diagnostic and therapeutic devices aimed at treating pain and addressing opioid use disorder (OUD). This grant seeks to support the creation of non-addictive device-based technologies, advancing them from early development to preclinical stages suitable for FDA approval, with a focus on demonstrating treatment efficacy through credible neural targets. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, for-profit entities, and tribal governments, with funding available for up to three years and a maximum budget of $750,000 annually. Interested parties should note that the application deadline is June 17, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NEI Translational Research Program for Therapeutics, aimed at accelerating the translation of innovative laboratory research into therapeutics for visual system diseases. This program seeks to fund multidisciplinary teams that can generate preclinical data leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications, with a focus on developing biological, pharmacological, and medical device interventions. The initiative underscores the federal commitment to translating biomedical research into practical therapies, ultimately enhancing patient care in ocular health. Grants of up to $1 million per year are available, with applications due by March 16, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.